Ofatumumab
112517
Phase 3 mab terminated
Quick answer
Ofatumumab for Leukaemia, Lymphocytic, Chronic is a Phase 3 program (mab) at Novartis Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novartis Pharmaceuticals
- Indication
- Leukaemia, Lymphocytic, Chronic
- Phase
- Phase 3
- Modality
- mab
- Status
- terminated